UNSPSC 51142559: Pergolide mesilate or mesylate

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C19H26N2S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55B9HQY616, chemically known as ergoline, 8-((methylthio)methyl)-6-propyl-, monomethanesulfonate, (8beta)- but more generally known as pergolide mesilate, which bears US NIH Compound Identifier 47812. European Medicines Agency schedules Pergolide mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03709MIG.

UNSPSC 51142559 Pergolide mesilate or mesylate is a Commodity code that in recent state and local procurement activity encompasses a much broader scope of pharmaceutical procurement than the code name alone suggests—specifically, generic multi-source pharmaceuticals, over-the-counter products, naloxone, and direct-to-manufacturer prescription fulfillment programs. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The solicitations reflect a mix of direct product procurement, cooperative purchasing frameworks, and exploratory market-intelligence gathering around alternative pharmacy benefit delivery models. Vendors responding to these opportunities must hold current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA authorization; maintain contractual relationships with authorized pharmaceutical wholesalers; and carry commercial general liability and professional liability insurance at specified minimums.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023 (though the posting date of June 30, 2026 indicates a metadata discrepancy); MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; and the Texas HHS Commission's RFI for direct-to-manufacturer prescription program capabilities, issued April 3, 2026 as an exploratory procurement mechanism to inform future formal solicitation design. The Minnesota cooperative purchasing agreement carries a two-year initial term with optional extensions, uses price competitiveness as the dominant evaluation factor (75 percent weight), and imposes a 3 percent administrative fee on all contract purchases along with performance penalties of $200 to $1,500 per violation for reporting or onboarding failures.